fbpx
Sign up now!
Don't show this again
Download the report!Continue to Site >
or wait 7 secs

Thank you for confirming your subscription!

(And remember, if ever you want to change your email preferences or unsubscribe, just click on the links at the bottom of any email.)
Tap to download the app
X
Share
X

REPORTS

Collect articles and features into your own report to read later, print or share with others

Create a New Report

Favorites

Read Later

Create a new report

Report title (required) Brief description (optional)
CREATE
X
NEXT
PORK POULTRY
follow us


You must be logged in to edit your profile.

Favorites Read Later My Reports PHT Special Reports
Pig Health Today is equipped with some amazing (and free) tools for organizing and sharing content, as well as creating your own magazines and special reports. To access them, please register today.
Sponsored by Zoetis

Pig Health Today | Sponsored by Zoetis

.
Featured Video Play Icon

Part 3: Chimeric vaccines combine strengths of each antigen to provide better coverage

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine?

In an interview with Pig Health Today, veterinary immunologist Meggan Bandrick, DVM, PhD, popped the hood on the US pork industry’s newest PCV2 vaccine and answered these questions in practical terms.

 

Watch the full interview or each part separately:

Full interview: What’s under the hood? Veterinary immunologist explains merits of new PCV2 vaccine

Part 1: Cell-mediated immunity critical to vaccine performance

Part 2: Why two PCV2 genotypes are better than one

Part 3: Chimeric vaccines combine strengths of each antigen to provide better coverage

 

 




Posted on November 28, 2018

tags: ,
RELATED NEWS
  • Scientist ‘pops the hood’ on US pork industry’s newest vaccine for PCV2

    What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine?

  • Part 1: Cell-mediated immunity critical to vaccine performance

    What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine?

  • Part 2: Why two PCV2 genotypes are better than one

    What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine?

  • Chimera technology offers better path to protection for PCV2

    DISCOVERIES, Issue 6: When PCV2 first became a problem in US swine herds, scientists looked at taking the immunogenic capsid gene from PCV2 and cloning it into the backbone of nonpathogenic PCV type 1 to produce a live chimeric vaccine for PCV2.




You must be logged in to edit your profile.

Google Translate is provided on this website as a reference tool. However, Poultry Health Today and its sponsor and affiliates do not guarantee in any way the accuracy of the translated content and are not responsible for any event resulting from the use of the translation provided by Google. By choosing a language other than English from the Google Translate menu, the user agrees to withhold all liability and/or damage that may occur to the user by depending on or using the translation by Google.